BACKGROUND: The impact of evidence-based guidelines and controlled trial data on use of cholesterol-lowering medications in older adults is unclear. OBJECTIVE: To examine whether utilization patterns of cholesterol-lowering medications in community-dwelling older adults changed following the release of the National Cholesterol Education Program Adult Treatment Panel III guidelines and results from the Prospective Study of Pravastatinin the Elderly at Risk in 2002. METHODS:Community-dwelling elderly individuals who were enrolled in the Health, Aging and Body Composition Study in 1997-1998 were followed for up to 11 years. An interrupted time series analysis with multivariable generalized estimating equations (GEEs) was used to examine changes in level and trend in cholesterol-lowering medication use before and after 2002, adjusting for sociodemographics, health-related behaviors, and health status. RESULTS:Cholesterol-lowering medication use increased nearly 3-fold from 14.9% in 1997-1998 to 42.6% in 2007-2008, with statins representing the most common class used (87-94%). Multivariable GEE results revealed no significant difference in the level of cholesterol-lowering medication use after 2002 (adjusted OR 0.95; 95% CI 0.89-1.02). Multivariable GEE results revealed that trend changes in the rate of increase in cholesterol-lowering medication declined after 2002 (adjusted ratio of ORs 0.92; 95% CI 0.89-0.95). CONCLUSIONS: The use of cholesterol-lowering medication increased substantially over a decade in community-dwelling elderly individuals but was not related to a change in level or trend following the release of the guidelines and evidence-based data.
RCT Entities:
BACKGROUND: The impact of evidence-based guidelines and controlled trial data on use of cholesterol-lowering medications in older adults is unclear. OBJECTIVE: To examine whether utilization patterns of cholesterol-lowering medications in community-dwelling older adults changed following the release of the National Cholesterol Education Program Adult Treatment Panel III guidelines and results from the Prospective Study of Pravastatin in the Elderly at Risk in 2002. METHODS: Community-dwelling elderly individuals who were enrolled in the Health, Aging and Body Composition Study in 1997-1998 were followed for up to 11 years. An interrupted time series analysis with multivariable generalized estimating equations (GEEs) was used to examine changes in level and trend in cholesterol-lowering medication use before and after 2002, adjusting for sociodemographics, health-related behaviors, and health status. RESULTS:Cholesterol-lowering medication use increased nearly 3-fold from 14.9% in 1997-1998 to 42.6% in 2007-2008, with statins representing the most common class used (87-94%). Multivariable GEE results revealed no significant difference in the level of cholesterol-lowering medication use after 2002 (adjusted OR 0.95; 95% CI 0.89-1.02). Multivariable GEE results revealed that trend changes in the rate of increase in cholesterol-lowering medication declined after 2002 (adjusted ratio of ORs 0.92; 95% CI 0.89-0.95). CONCLUSIONS: The use of cholesterol-lowering medication increased substantially over a decade in community-dwelling elderly individuals but was not related to a change in level or trend following the release of the guidelines and evidence-based data.
Authors: S Riahi; K Fonager; E Toft; L Hvilsted-Rasmussen; J Bendsen; S Paaske Johnsen; H T Sørensen Journal: Br J Clin Pharmacol Date: 2001-09 Impact factor: 4.335
Authors: James Shepherd; Gerard J Blauw; Michael B Murphy; Edward L E M Bollen; Brendan M Buckley; Stuart M Cobbe; Ian Ford; Allan Gaw; Michael Hyland; J Wouter Jukema; Adriaan M Kamper; Peter W Macfarlane; A Edo Meinders; John Norrie; Chris J Packard; Ivan J Perry; David J Stott; Brian J Sweeney; Cillian Twomey; Rudi G J Westendorp Journal: Lancet Date: 2002-11-23 Impact factor: 79.321
Authors: E M Simonsick; A B Newman; M C Nevitt; S B Kritchevsky; L Ferrucci; J M Guralnik; T Harris Journal: J Gerontol A Biol Sci Med Sci Date: 2001-10 Impact factor: 6.053
Authors: Nathalie de Rekeneire; Ronica N Rooks; Eleanor M Simonsick; Ronald I Shorr; Lewis H Kuller; Ann V Schwartz; Tamara B Harris Journal: Diabetes Care Date: 2003-07 Impact factor: 19.112
Authors: Joshua S Benner; Robert J Glynn; Helen Mogun; Peter J Neumann; Milton C Weinstein; Jerry Avorn Journal: JAMA Date: 2002 Jul 24-31 Impact factor: 56.272
Authors: Tracy L Kinsey; Til Stürmer; Charles Poole; Kenneth J Rothman; Robert J Glynn Journal: Pharmacoepidemiol Drug Saf Date: 2018-12-19 Impact factor: 2.890
Authors: Michelle C Odden; Mark J Pletcher; Pamela G Coxson; Divya Thekkethala; David Guzman; David Heller; Lee Goldman; Kirsten Bibbins-Domingo Journal: Ann Intern Med Date: 2015-04-21 Impact factor: 25.391
Authors: Zhen Zhou; Andrea J Curtis; Michael E Ernst; Joanne Ryan; Sophia Zoungas; Rory Wolfe; John J McNeil; Anne M Murray; Christopher M Reid; Enayet K Chowdhury; Robyn L Woods; Andrew M Tonkin; Mark R Nelson Journal: Eur J Clin Pharmacol Date: 2021-10-26 Impact factor: 2.953